Cancer Research Targets  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kondo, T.
Right arrow Articles by Yasui, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kondo, T.
Right arrow Articles by Yasui, W.
[Cancer Research 64, 523-529, January 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Expression of POT1 is Associated with Tumor Stage and Telomere Length in Gastric Carcinoma

Tomohiro Kondo1, Naohide Oue1, Kazuhiro Yoshida2, Yoshitsugu Mitani1, Kazuhito Naka3, Hirofumi Nakayama1 and Wataru Yasui1

1 Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima;
2 Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; and
3 Department of Molecular Biology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

Pot1, a telomere end-binding protein in fission yeast and human, is proposed not only to cap telomeres but also to recruit telomerase to the ends of chromosomes. No study has been performed regarding Pot1 expression status in human cancers. Thus, we examined POT1 mRNA expression in 51 gastric cancer (GC) tissues and evaluated telomere length and 3' telomeric overhang signals in 20 of the 51 GC tissues. Quantitative reverse transcription-PCR analysis showed that POT1 expression levels in the tumor relative to those in nonneoplastic mucosa (T/N ratio) were significantly higher in stage III/IV tumors than in stage I/II tumors (P = 0.005). Down-regulation of POT1 (T/n < 0.5) was observed more frequently in stage I/II GC (52.4%, 11 of 21) than in stage III/IV GC (23.3%, 7 of 30; P = 0.033), whereas up-regulation of POT1 (T/n > 2.0) was observed more frequently in stage III/IV GC (33.3%, 10 of 30) than in stage I/II GC (9.5%, 2 of 21; P = 0.048). POT1 expression levels showed decreased in accordance with telomere shortening (r = 0.713, P = 0.002). In-gel hybridization analysis showed that 3' telomeric overhang signals decreased in accordance with decreases in POT1 expression levels (r = 0.696, P = 0.002) and telomere shortening (r = 0.570, P = 0.013). Reduced POT1 expression was observed in GC cell lines with telomeres shortened by treatment with azidothymidine. In addition, inhibition of Pot1 by antisense oligonucleotides led to telomere shortening as well as inhibition of telomerase activity in GC cells. Moreover, inhibition of Pot1 decreased 3' overhang signals and increased the frequency of anaphase bridge (P = 0.0005). These data suggest that Pot1 may play an important role in regulation of telomere length and that inhibition of Pot1 may induce telomere dysfunction. Moreover, changes in POT1 expression levels may be associated with stomach carcinogenesis and GC progression.




This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
T. Else
Telomeres and telomerase in adrenocortical tissue maintenance, carcinogenesis, and aging
J. Mol. Endocrinol., October 1, 2009; 43(4): 131 - 141.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Lin, J. Gu, C. Lu, M. R. Spitz, and X. Wu
Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer.
Clin. Cancer Res., October 1, 2006; 12(19): 5720 - 5725.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Zaffaroni, R. Villa, U. Pastorino, R. Cirincione, M. Incarbone, M. Alloisio, M. Curto, S. Pilotti, and M. G. Daidone
Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres
Clin. Cancer Res., April 15, 2005; 11(8): 2832 - 2839.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Q. Yang, Y.-L. Zheng, and C. C. Harris
POT1 and TRF2 Cooperate To Maintain Telomeric Integrity
Mol. Cell. Biol., February 1, 2005; 25(3): 1070 - 1080.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.